Summary of Key Points
The two global giants in the weight loss medication industry, Eli Lilly and Novo Nordisk, are accelerating the launch of their next-generation weight loss drugs (both oral and injectable) in China. Domestic companies have already begun preparing generic versions of these new drugs, but due to patent and data protection restrictions, generic drugs cannot be commercialized in the short term (with an expected market availability after 2027). The launch of generic drugs will likely trigger a price war, while the original research companies plan to maintain their market dominance through continuous innovation.
Detailed Analysis
1. The Next Generation of Weight Loss Drugs is on the Way: More Convenient Oral Forms, with Giants Competing for the Chinese Market
Eli Lilly and Novo Nordisk, leaders in the weight loss medication sector, have both scheduled the launch of their next-generation products in China:
- Eli Lilly: Its oral weight loss drug orforglipron is expected to be available in China later this year (no need for injections, just take a pill, which is more convenient than the current injectable version); another three-target injectable drug, liraglutide, has entered the global phase III clinical trial stage.
- Novo Nordisk: Plans to submit an application for the launch of its new oral semaglutide in China soon (semaglutide is a popular weight loss drug, but it has been mainly available in injectable form so far; the oral version is more appealing to consumers.)
In simple terms: The next generation of weight loss drugs are more convenient (oral instead of injectable), and both companies want to be the first to enter the Chinese market to capture a share.
2. Domestic Companies are Preparing Generics in Advance: Waiting for Patents to Expire
Seeing the new drug developments by the giants, domestic pharmaceutical companies have started preparing generic versions:
- Nuotai Biology: Its subsidiary Hangzhou Naoao’s semaglutide tablet generic has been approved for clinical trials; they are also conducting “pilot production” tests for liraglutide (small-scale production to prepare for mass manufacturing).
- Sinoda Pharmaceutical: Obtained the synthesis patent for liraglutide last year and claims it can produce the drug at a lower cost.
In simple terms: Domestic companies are getting ahead of the game by preparing generic versions, but they cannot sell them yet—they have to wait until the patents for the original drugs expire before they can enter the market and share in the sales.
3. Why Can’t Generics Be Sold Yet? Patents and Data Protection Are the Hurdles
The main reasons why generic drugs cannot be launched immediately are:
- Patent Protection: The patents for the original drugs have not expired, so generic companies cannot produce them freely (for example, liraglutide’s patent is still in effect).
- Data Protection: Even if the compound patents expire, the clinical trial data of the original drugs are protected, and generic companies must conduct their own trials to apply for approval. For instance, Novo Nordisk’s semaglutide has an expired compound patent, but since the data protection period has not ended, generic versions are not expected to be available until the second quarter of 2027.
In simple terms: The original research companies invested heavily in research and development; they need to profit from their investments before allowing generics to enter the market.
4. What Happens When Generics Are Launched? A Price War, with Patients Benefiting
The biggest impact of generic drugs is a decrease in prices:
- Original drugs are expensive due to high research and development costs (for example, current semaglutide injectables can cost several thousand yuan per month).
- Generic drugs, being cheaper, will enter the market and drive down prices; original companies will have to lower their prices to compete. The end result is that more people will be able to afford weight loss medications.
In simple terms: It’s similar to how generic versions of blood pressure and diabetes medicines reduced prices significantly—patients no longer need to worry about high medication costs.
5. Are Original Research Companies Unconcerned About Generics? They Rely on Continuous Innovation to Stay Ahead
Facing the threat of generics, original research companies have their own strategies:
- Novo Nordisk’s CEO said, “We welcome the entry of generic drugs into the market. We have already recouped our research and development costs during the patent period, so price reductions are expected. This will make more patients able to afford the drugs. However, we will win the market through innovation—our next-generation products are better than the previous ones (for example, oral versions instead of injectables), and we are already working on new drugs.”
In simple terms: Even if generics copy our older products, we will always be one step ahead with our newer innovations.
Conclusion
The competition for the next generation of weight loss drugs has begun, and Chinese patients will soon have more convenient oral options available. Although generic drugs will take a few years to hit the market, they will make the medication more affordable in the long run. Original research companies will continue to lead through continuous innovation. For consumers, this means that weight loss medications will become increasingly accessible and inexpensive.